NCT07485205 Establishing Normative Urodynamics Parameters for the Glean Urodynamics System in Healthy Adults
| NCT ID | NCT07485205 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bright Uro |
| Condition | Lower Urinary Tract Symptoms (LUTS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2026-03-31 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 72 participants in total. It began in 2026-03-31 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A prospective, open-label, single arm interventional trial to establish normative reference ranges for urodynamics parameters in healthy adult participants using using the Glean Urodynamics System.
Eligibility Criteria
Inclusion Criteria: 1. Healthy male and female adults ages 18 to 45 years. 2. Patient is able to read, write, and communicate in English. 3. Patient is able to provide informed consent. 4. Patient owns, can independently operate, and is willing to use a smart device for study data collection purposes Exclusion Criteria: 1. Patient with any prior pregnancy (gravida ≥1), is currently pregnant (as confirmed by urine pregnancy test or medical history), or intends to become pregnant during the study period. 2. Patient has one or more symptoms indicative of a symptomatic urinary tract infection (UTI) (i.e., fever, costovertebral angle pain or tenderness, suprapubic tenderness, worsening urinary frequency, worsening urgency, and/or dysuria). 3. Patient has a known history of urological conditions (e.g., recurrent UTIs, incontinence, symptomatic benign prostatic hyperplasia, neurogenic bladder, interstitial cystitis, urinary retention, any genitourinary cancer). 4. Patient has a known history of neurological conditions that can affect central nervous system function. 5. Patients with a current or prior diagnosis of diabetes mellitus (Type 1 or Type 2). 6. Patient is currently taking medications that may affect urological functions (e.g., diuretics, anticholinergics, alpha-blockers). 7. Patient has abnormal urinary habits if one or more of the following bladder events are reported on any day of the 3-day bladder diary: urinary frequency ≥ 8 times/day, ≥ 1 nocturia episode, ≥ 1 leak event, or ≥ 1 urgency event. 8. Patient has a total score on the Lower Urinary Tract Dysfunction Research Network Symptom Index-10 (LURN SI-10) questionnaire greater than 0; a total score of 1 is acceptable only if the sole positive response is urinary frequency of 4-7 times per day. 9. Patient has a urostomy and/or colostomy. 10. Patient has an atypical anatomic structural variation or has had a previous surgical intervention that has permanently changed structural anatomy anywhere along their lower urinary tract (urethra, pelvic floor, urethral sphincter, and/or bladder wall) that the principal investigator deems might compromise the placement or retention of the Glean sensors during the study (e.g., strictures). 11. Patient has a Pelvic Organ Prolapse Quantification (POP-Q) of Grade III or higher (i.e., most distal portion of the prolapse protrudes more than 1 centimeter below the hymen). 12. Patient would not be appropriate for this study as determined by the Principal Investigator.
Contact & Investigator
Brittany Carter
STUDY DIRECTOR
Bright Uro
Frequently Asked Questions
Who can join the NCT07485205 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Lower Urinary Tract Symptoms (LUTS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07485205 currently recruiting?
Yes, NCT07485205 is actively recruiting participants. Contact the research team at brittany@brighturo.com for enrollment information.
Where is the NCT07485205 trial being conducted?
This trial is being conducted at Phoenix, United States, Tucson, United States, Boulder, United States.
Who is sponsoring the NCT07485205 clinical trial?
NCT07485205 is sponsored by Bright Uro. The principal investigator is Brittany Carter at Bright Uro. The trial plans to enroll 72 participants.